Literature DB >> 12735563

Right ventricular cardiomyoplasty: 10-year follow-up.

Juan C Chachques1, Pantelis G Argyriadis, Guy Fontaine, Jean-Louis Hebert, Robert A Frank, Nicola D'Attellis, Jean-Noël Fabiani, Alain F Carpentier.   

Abstract

BACKGROUND: Chronically depressed right ventricular (RV) function presents an unsolved therapeutic challenge in cardiac surgery. Despite recent advances in medical and surgical therapies, prognosis remains poor and patient's quality of life and mortality are frequently unacceptable. The aim of this study is to present the first clinical report and long-term results of RV dynamic cardiomyoplasty applied in patients with RV failure caused by isolated RV cardiomyopathies.
METHODS: Seven consecutive patients (5 males, 2 females; mean age, 40 +/- 9 years; range, 15 to 63 years) from a series of 113 cardiomyoplasty procedures performed at Broussais and Pompidou Hospitals were evaluated. The mean duration of follow-up was 10 +/- 3.5 years. All patients had predominant RV dysfunction, associated with tricuspid regurgitation in 6 patients. The cause of RV failure was arrhythmogenic cardiomyopathy (4 patients), ischemic (2 patients), and Uhl's disease (1 patient), and endomyocardial fibrosis (1 patient). Six patients were in preoperative New York Heart Association functional class III and 1 was in intermittent class III/IV. The mean preoperative ejection fraction (measured by isotopic technique) was 18% +/- 5.7% for the right ventricle and 40% +/- 13% for the left ventricle. Right ventricular dynamic cardiomyoplasty consists of wrapping the RV free walls with the left latissimus dorsi muscle flap. The distal part of the latissimus dorsi muscle is fixed to the diaphragm and then electrostimulated. Six patients required associated tricuspid valve surgery.
RESULTS: There were no perioperative deaths. The mean duration of follow-up was 10 +/- 3.5 years. Six patients are alive with a remarkable quality of life, 4 are in New York Heart Association functional class I and 2 are in class II. One patient who was in New York Heart Association functional class II died in postoperative year 7 caused by stroke. At last follow-up, mean RV ejection fraction was 33% +/- 11.8% and left ventricular ejection fraction was 52% +/- 12.6%.
CONCLUSIONS: The results of this long-term study demonstrate hemodynamic and functional improvements after RV cardiomyoplasty without perioperative mortality, no long-term malignant arrhythmias, and RV dysfunction related deaths. We believe that RV cardiomyoplasty, associated with tricuspid valve surgery when required, could be an effective treatment for severe RV failure.

Entities:  

Mesh:

Year:  2003        PMID: 12735563     DOI: 10.1016/s0003-4975(02)04823-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

Review 1.  Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare "disease of the desmosome" with multiple clinical presentations.

Authors:  Thomas Herren; Philipp A Gerber; Firat Duru
Journal:  Clin Res Cardiol       Date:  2009-02-09       Impact factor: 5.460

2.  Arrhythmogenic right ventricular cardiomyopathy. What is needed for a cure?

Authors:  G Thiene; I Rigato; K Pilichou; D Corrado; C Basso
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

3.  [Uhl's disease--rare cause of chronic right heart failure].

Authors:  Christian Cornelissen; Dirk Frechen; Karin Schreiner; Stefan Krüger
Journal:  Med Klin (Munich)       Date:  2009-12-30

4.  Development of bioartificial myocardium using stem cells and nanobiotechnology templates.

Authors:  Juan Carlos Chachques
Journal:  Cardiol Res Pract       Date:  2010-12-29       Impact factor: 1.866

Review 5.  Right ventricular dysplasia: management and treatment in light of current evidence.

Authors:  Amr Idris; Syed Raza Shah; Ki Park
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

6.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard N W Hauer; Frank E Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; Na Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Circulation       Date:  2015-07-27       Impact factor: 29.690

Review 7.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.

Authors:  Domenico Corrado; Thomas Wichter; Mark S Link; Richard Hauer; Frank Marchlinski; Aris Anastasakis; Barbara Bauce; Cristina Basso; Corinna Brunckhorst; Adalena Tsatsopoulou; Harikrishna Tandri; Matthias Paul; Christian Schmied; Antonio Pelliccia; Firat Duru; Nikos Protonotarios; N A Mark Estes; William J McKenna; Gaetano Thiene; Frank I Marcus; Hugh Calkins
Journal:  Eur Heart J       Date:  2015-07-27       Impact factor: 29.983

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.